

MYALGIC ENCEPHALOMYELITIS

CHRONIC FATIGUE SYNDROME

FROM HARM TO HELP

DR CATHY STEPHENSON

M.E. Myalgic Encephalomyelitis also known as Chronic Fatigue Syndrome (CFS) Tapanui Flu, or ME/CFS

MYALGIC ENCEPHALOMYELITS

ME/CFS is a serious, chronic, complex and multisystem disease that frequently and dramatically limits the activities of affected patients.

(National Academy of Medicine 2015)

Classified in ICD 10 as a neurological condition

THE DOCTOR'S EXPERIENCE

- Medical training has little/no ME/CFS specific information
- Multisystem and highly variable condition (both within and between patients)
- No diagnostic test and no clear agreement about clinical criteria
- Multiple contributing, co-occurring and confounding conditions
- Medical system discourages integrating knowledge
- Autonomic dysregulation may be mistaken for anxiety

Doctors are perplexed. "If it can't be measured and I don't understand it, it must be mental health".

ME/CFS is PUS (psychiatrically unexplained symptoms)

Rata Actea roctor + Educate

HOW TO TREAT ME/CFS

CME







A PARADIGM SHIFT

1969.
ME included (and remains) in the ICD as
Neurological disease.

1988.
CDC renames ME as
Chronic Fatigue
Syndrome.
It becomes a 'syndrome
of fatigue'.
Psychological models
proliferate.

2011.
PACE trial erroneously concludes
Graded Exercise and
Cognitive Behavioural
Therapy may be curative.

Recommendations included in all major guidelines.

2011 to current.
PACE trial
acknowledged as
methodologically
flawed.


CDC apologises.

2021 NICE guidelines redrafted.

Graded Exercise and Cognitive Behavioural Therapy are NO LONGER RECOMMENDED for ME and have been shown to be harmful. No evidence exists for psychological models of ME.


NIH RESEARCH FUNDING 2010-2014

One Year of Funding for MS would Fund 23 Years of Research into ME



MISINFORMATION HAS DERAILED RESEARCH AND IMPACTED CARE OF PATIENTS





PATHOPHYSIOLOGY


RESEARCH STUDIES DESCRIBE PATHOPHYSIOLOGICAL CHANGES

• IMMUNE SYSTEM ABNORMALITIES

CELLULAR METABOLISM ABNORMALITIES

NEUROENDOCRINE DISTURBANCES

BLOOD PRESSURE and HEART RATE ABNORMALITIES



EPIDEMIOLOGY

- Prevalence is 0.2 1%. 85-90% are undiagnosed 20,000-40,000 NZers
- Ratio of Female: Male 3+:1
- Affects all ages, races and socioeconomic backgrounds
- Genetics plays a role

COURSE

- Around 2/3 of ME cases are triggered by an acute infection.
- Less common triggers include non-infectious immune provocations
- Around 25% of people have a gradual onset with no obvious trigger
- Less than 5% fully recover

SPECTRUM OF SEVERITY

ME is a Spectrum Disorder from MILD to VERY SEVERE 'Mild' cases involve the loss of at least 50% of normal function

MILD

May work but only at expense of other areas of life.



MODERATE

Mostly housebound May use walking aid



SEVERE

Mostly bed-bound.

May rely on

wheelchair & carers.




VERY SEVERE

Fully bed-bound.
Often can't speak.
Untreatable pain.
Often require
nutritional support.



QUALITY OF LIFE



 People with ME are often more functionally impaired than people with type 2 diabetes, multiple sclerosis, congestive heart failure and end stage kidney disease.

 They suffer a lower quality of life than people with cancer, stroke, kidney failure and schizophrenia.

SYMPTOM PRESENTATION

FLU-LIKE SYMPTOMS REDUCED FUNCTIONALITY DYSPNEA PAIN MUSCLE PAIN MUSCLE FATIGABILITY & WEAKNESS TEMPERATURE DYSREGULATION POST-EXERTIONAL MALAISE PHOTOPHOBIA HYPERSOMNIA MCAS CHEMICAL SENSITIVITES SWOLLEN LYMPH NODES ANAEMIA CHEST PAIN GASTROINTESTIONAL DYSFUNCTION HYPERACUSIS SLOWED SPEECH INSOMNIA PROFOUND FATIGUE POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME HEADACHES MOOD SWINGS FOOD INTOLERANCES JOINT PAIN UNREFRESHING SLEEP DEPRESSION D DEFICIENCY ALCOHOL INTOLERANCE WEIGHT GAIN/LOSS ANXIETY HYPOGLYCAEMIA POOR COORDINATION JOINT HYPERMOBILITY COGNITIVE IMPAIRMENT BLURRED VISION MIGRAINES ALLODYNIA SYNCOPE CCI ORTHOSTATIC INTOLERANCE TACHYCARDIA DYSPHASIA

DIAGNOSTIC CRITERIA


FLU-LIKE SYMPTOMS REDUCED FUNCTIONALITY PAIN MUSCLE PAIN DYSPNEA MUSCLE FATIGABILITY & WEAKNESS TEMPERATURE DYSREGULATION POST-EXERTIONAL MALAISE PHOTOPHOBIA HYPERSOMNIA MCAS CHEMICAL SENSITIVITES SWOLLEN LYMPH NODES ANAEMIA GASTROINTESTIONAL DYSFUNCTION PROFOUND FATIGUE SLOWED SPEECH INSOMNIA POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME HEADACHES MOOD SWINGS FOOD INTOLERANCES JOINT PAIN UNREFRESHING SLEEP D DEFICIENCY ALCOHOL INTOLERANCE WEIGHT GAIN/LOSS ANXIETY HYPOGLYCAEMIA POOR COORDINATION JOINT HYPERMOBILITY COGNITIVE IMPAIRMENT **BLURRED VISION** MIGRAINES ALLODYNIA SYNCOPE ORTHOSTATIC INTOLERANCE TACHYCARDIA DYSPHASIA

DIAGNOSIS

Sx present

6 months

at least half the time



ASSESS DIAGNOSE INVESTIGATE DIFFERENTIALS REFER

Institute of Medicine (IOM/NAM) Criteria for ME/CFS 2015.

ROLE OF THE GENERAL PRACTITIONER

ASSESS,
INVESTIGATE
DIFFERENTIALS,
DIAGNOSE,
REFER

ADVOCATE

WINZ, Regional Health Schools, LTC-CHC pathway.

FORMULATION

An evidence-based shared understanding between patient, GP and other providers.

SUPPORT

Validate the experience and anticipate secondary disability.

SYMPTOM MANAGEMENT

Agree on a hierarchy of need and focus on one symptom at a time.

PACING

ME/CFS Suspected?
Continue
investigation AND
commence pacing.

WHAT IS POST-EXERTIONAL MALAISE (PEM)?

It is defined by a worsening of symptoms (not just fatigue) in the period following exertion. Is not the same as post-exertional fatigue or exercise intolerance.

POST- EXERTIONAL MALAISE (PEM)

Is Unique to ME

Is Required for a Diagnosis of ME

Is Key to
Distinguish
ME From
Other Diseases


Is Delayed 24 - 72 hrs After Exertion May Last
Days, Weeks
or Much
Longer

Can Result in a Lowered Baseline

Exercise physiology research has revealed the pathology of PEM

- Marked abnormalities on two day cardiopulmonary exercise testing.
- Characteristic deterioration in exercise capacity on the second day.
- ME is not caused by deconditioning


PRE-ILLNESS LEVEL OF FUNCTIONING



- Bachelor of Design with career as an Interior Architect
- Then ICU nurse with post graduate qualifications
- Mother of two
- Busy and high functioning
- 10 years of mild undiagnosed illness
- Pushed through and became severe in the context of overexercising.


WILL I SEE PEM IN THE CLINIC?

WHAT YOU MIGHT SEE....



A PATIENT WITH MODERATE / SEVERE ME ON A GOOD DAY
OFTEN DOESN'T APPEAR UNWELL

2019 DIAGNOSED WITH ME/CFS



After developing ME/CFS, this is new baseline


- Housebound 70% of time
- Unable to work
- Often unable to care for children
- Unable to cook/clean/household chores
- Often unable to wash hair/shower
- Use of e-scooter for mobility
- Unable to walk more than a few hundred metres at a time



AFTER OVEREXERTION.... SEVERE ME

PEM

- Profound fatigue
- Slurred speech
- Unable to leave bed
- Difficult to chew food
- Intense muscle fatigue with weakness
- Arrhythmias (SVT, elevated rate,
 2nd degree block wenckebach)
- Dizziness (cannot tolerate being upright)
- Shortness of breath
- Cognitive dysfunction
- Unable to tolerate light or sound
- Unable to care for self or children



"I feel like I'm drowning, I don't know which way is up, I can't see, I can't find my way out. I can hear voices and movement but can't make sense of them. I want to find the surface for air but I'm weighed down under this immense fatigue. It can be terrifying". Description of PEM from patient.

INVESTIGATIONS

Routine blood tests – complete blood count, C-reactive protein, ferritin, electrolytes, renal and liver function tests, calcium, magnesium, blood glucose, thyroid function tests, vitamin B12, folate, vitamin D and coeliac antibodies



Other clinically indicated tests- immunoglobulins, antinuclear antibodies, rheumatoid titres, creatinine kinase and cortisol.

If associated with a viral illness, consider – Epstein–Barr virus, cytomegalovirus and HIV testing. Also consider testing for Lyme disease in patients who have travelled outside New Zealand, if symptoms indicate.

Covid 19 is now being shown to be a significant trigger.


DIAGNOSTIC CONSIDERATIONS - OVERLAPPING AND COMORBID CONDITIONS ARE THE NORM



ASSESS
DIAGNOSE
INVESTIGATE
DIFFERENTIALS
REFER

A ME/CFS

PEM
Loss of function/Fatigue
Unrefreshing sleep
Ol and/or cognitive
impairment



B Overlapping Conditions (sample)

Autonomic Dysfunction (eg POTS)
Mast Cell Activation Syndrome
Fibromyalgia
Hypermobility Syndromes (eg EDS)
Cranio-Cervical Instability
Small Fiber Polyneuropathy

Other Autoimmune Conditions

For a complete list of overlapping conditions, differential diagnoses and investigations refer to NZ Doctor ME/CFS

SYMPTOM MANAGEMENT

STEPWISE SYMPTOM MANAGEMENT



- Together agree on a stepwise symptom hierarchy.
- List symptoms from most to least troubling.
- Tackle one thing at a time, in line with the symptom hierarchy.
- Sleep, pain and cognitive issues are common problems that GPs are well versed in managing.
- Approach symptom management for ME/CFS patients the same as for anyone else but remember these symptoms tend to be more persistent and resistant to treatment in this group.

SYMPTOM MANAGEMENT


Management Considerations

- Consider comorbid and differential conditions. LOTS of things can look like ME/CFS.
- Medication sensitivity is the rule. Go low and slow.
 Minimise polypharmacy.
- There is no definitive evidence for supplementation but B12 is commonly recommended.
- Food intolerances and sensitivities are common.
- Patients may be aware of emerging evidence be prepared to partner with them and experiment.

SYMPTOM
MANAGEMENT
Focus on the
patients top
priority

If ME/CFS is suspected commence pacing.

ORTHOSTATIC INTOLERANCE



ASSESS
DIAGNOSE
INVESTIGATE
DIFFERENTIALS
REFER

- Many conditions look and feel like ME/CFS.
- PEM must be present for a diagnosis of ME/CFS.

ASSESSING POTS



Poor Man's Tilt / Nasa Lean Test / Passive Stand Test

Sustained increase in HR to >30 bpm over baseline (>40 bpm for children/adolescents) OR above 120 bpm.







ASSESS
DIAGNOSE
INVESTIGATE
DIFFERENTIALS
REFER

MANAGING POTS

MANAGEABLE AS AN ASPECT OF ME

First Line

- Rationalise medications that may be contributing
- Increase fluid above 21
- Increase salt intake up to 8 gm
- Compression
- Physical manoeuvres

Second line (in consultation with secondary care)

- Fludrocortisone, midodrine, beta blockers, mestinon
- Ivabradine (very common use in USA and UK available in NZ but delays due to demand from post covid POTS)

SYMPTOM MANAGEMENT

Agree on a hierarchy of need and focus on one symptom at a time


PACING: REDUCE THE IMPACT OF PEM BY LEAVING SOME FUEL IN THE TANK

PACING improves quality of life and reduces PEM.

PACING

- Expend less energy than is available and stay within the Energy Envelope below threshold that triggers PEM
- Energy expenditure includes physical, cognitive and emotional activity.
- Expect variability of energy envelope.
- Break activities down into short bursts.
- Intersperse with rest.





Rest means absolutely minimal activity and minimal stimulation.

WHAT PATIENTS WANT US TO KNOW

- Accept that your patient may be the expert partner with your patient.
- Emerging treatment may take decades to be approved. Within the limits of safety be prepared to experiment.
- Fatigue is a symptom but it is not the defining symptom.
- Provide flexible appointment such as phone consultations coming to the office will trigger PEM for most.
- · Assist with practical issues such as benefit applications, referrals to health school.
- Be vigilant for secondary disability this is a hard road to walk
- ME is NOT a mental illness, patients are experiencing real and distressing physical symptoms.

TAKE HOME MESSAGES

- Complex, multisystem disorder
- Diagnostic clarity and validity is improving
- GET is not curative and may be harmful
- CBT is supportive but not curative
- Symptomatic treatment can be effective (eg POTS, sleep, pain)
- Listen to your patients and partner with them it might be a long journey

